GlassScriptPhysician profile
John B Cason
NPI 1255494001
$14,356.45
in general payments reported to CMS, 2019-2025
14 companies · $4,266 in 2025
The $4,266 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $14.82 · 2021: $83.69 · 2022: $1,461 · 2023: $3,602 · 2024: $4,736 · 2025: $4,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,625 · Food and Beverage: $4,954 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,625.00 |
| Food and Beverage | $4,953.72 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $6,225.49 | 2022-2025 | Kxl System, Ce-Marked Kxla System, Kxl System (Not Refurbished) |
| Carl Zeiss Meditec USA, INC. | $3,664.46 | 2021-2025 | Visumax, Mel 90, Veracity Surgical |
| Alcon Vision LLC | $1,752.82 | 2019-2025 | Clareon, Wavelight Refractive Suite, Clareon Panoptix Pro |
| Rxsight INC | $659.96 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $508.14 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $395.85 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $319.38 | 2024-2025 | Envista Envy Iol, Envista Aspire Toric Iol, Envista Envy |
| Carl Zeiss Meditec, INC. | $296.10 | 2019-2024 | Veracity Surgical, Visumax |
| Oyster Point Pharma, INC. | $168.48 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $124.85 | 2022 | |
| Dompe US, INC. | $97.76 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $88.10 | 2025 | Vevye |
| Abbvie INC. | $30.85 | 2023 | Lumigan, Alphagan P |
| Integra Lifesciences Corporation | $24.21 | 2023 | Durasorb Monofilament Mesh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.